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Tissue engineering employs scaﬀolds, cells, and stimuli brought together in such a way as to mimic the functional architecture
of the target tissue or organ. Exhilarating advances in tissue engineering and regenerative medicine allow us to envision in vitro
creation or in vivo regeneration of cardiovascular tissues. Such accomplishments have the potential to revolutionize medicine and
greatly improve our standard of life. However, enthusiasm has been hampered in recent years because of abnormal reactions at
the implant-host interface, including cell proliferation, ﬁbrosis, calciﬁcation and degeneration, as compared to the highly desired
healing and remodeling. Animal and clinical studies have highlighted uncontrolled chronic inﬂammation as the main cause of
theseprocesses.Inthisminireview,wepresentthreecasestudieshighlightingtheimportanceofinﬂammationintissueengineering
heart valves, vascular grafts, and myocardium and propose to focus on the endothelial barrier, the “ﬁnal frontier” endowed with
the natural potential and ability to regulate inﬂammatory signals.
1.Introduction
Biomedical engineers in the cardiovascular tissue engineer-
ing (CVTE) arena dare to “boldly go where no man has gone
before”;theymixscaﬀoldswithcells,addmechanicalstimuli,
growth factors, and other ingredients, culture the constructs
in vitro for maturation and ...voil´ a: a newly created surro-
gate structure ready to replace an inﬂamed, thrombotic,
atherosclerotic, calciﬁed, or infected cardiovascular tissue
[1]. Tissue engineering and regenerative medicine are at the
footsteps of clinical translation and hold great therapeutic
potential. However, progress in the ﬁeld is critically ham-
pered by uncontrolled, chronic implant-host interactions
and more speciﬁcally by chronic inﬂammation.
When challenged by an implanted biomaterial, the
body selects one or more of its three defense mechanisms
existent in the “armamentarium”: hemostasis/coagulation,
immune reactions, and inﬂammation [2] .W h i l ew eh a v e
the ability to control the ﬁrst two mechanisms relatively
well using drugs, chronic cardiovascular inﬂammation is
more diﬃcult to manage. Moreover, the clinical conse-
quences of chronic inﬂammation including uncontrolled cell
proliferation, ﬁbrosis, calciﬁcation, and sclerosis are almost
impossible to treat pharmaceutically [3, 4].
As we will describe in this minireview, technical chal-
lenges in CVTE are plentiful, but the “ﬁnal frontier” is
the healthy, quiescent endothelium [5]. This monolayer
of cells that naturally covers all blood-contacting tissues
acts as a dynamic and selective barrier by maintaining a
nonthrombogenic surface, controls the transfer of molecules
across the vascular wall, modulates blood ﬂow and vascular
resistance, regulates immune and inﬂammatory reactions
and also interacts with underlying cells to regulate their
growth and proliferation. The activation of the endothe-
lium by cytokines, bacterial products, hemodynamic forces,
lipids, and other agents induces expression of a new and
radically diﬀerent cell phenotype. Activated endothelium
expresses new adhesion molecules on its surface and secretes
chemokines, growth factors, vasoactive mediators, and
coagulation proteins. Dysfunctional endothelium becomes2 International Journal of Inﬂammation
adhesive to inﬂammatory cells, exposes thrombogenic sur-
faces, and thus promotes inﬂammation, atherosclerosis, and
thromboembolism [6–8] Activation of other cardiovascular
cells such as vascular smooth muscle cells and cardiac
ﬁbroblasts also contributes signiﬁcantly to cardiovascular
pathology by initiating intimal hyperplasia [9] and cardiac
ﬁbrosis [10], respectively.
Overall, the presence, integrity, and state of activation
of an endothelial surface at the implant-host interface can
“make or break” a tissue-engineered cardiovascular device. It
is, thus, clear that the secret to successful CVTE is gaining
control over inﬂammation by modulating the endothelium,
the “ultimate interface”.
2.InﬂammationinCardiovascular
TissueEngineering
After implantation, cardiovascular devices typically undergo
a process similar to wound healing [3]. Following an initial
blood-material interaction where ﬁbrin is deposited on
the luminal surface, inﬂammatory processes occur around
the implanted construct. In initial stages, neutrophils and
monocytes migrate to the interface between the implant
surface and the injured tissue. During the granulation
phase, phagocytes remove debris due to trauma and then
provide signals for ﬁbroblasts and smooth muscle cells to
start remodeling. This phase lasts 2-3 weeks in humans
and ideally will culminate with complete healing. However,
the inﬂammatory response may continue for months or
years and, thus, may lead to chronic inﬂammation. The
consequences of this deleterious process include intimal
thickening, tissue overgrowth (pannus formation), foreign
body reactions, granulation, ﬁbrosis, and ectopic calciﬁ-
cation. The mechanisms of these pathological phenomena
are not fully understood, but it is known that mono-
cytes/macrophagesareobservedwithinimplantedconstructs
until they fully degrade or, if the implant is not degradable,
for the life of the implant [4]. Mineralization of syn-
thetic or biologic scaﬀolds is end-stage pathology, generally
irreversible and untreatable. It is also commonly accepted
that calciﬁcation may not occur if scaﬀolds degrade slowly
and the matrix is capable of remodeling [11]. In most
studies on chronic inﬂammation reported to date, a “diﬀuse
mononuclear inﬁltrate” was described together with “frus-
trated macrophages” a.k.a., foreign body giant cells [12].
The latter secrete large amounts of proteases and reactive
oxygen species which in turn promote implant degradation,
loosening, and eventual failure. Recent evidence suggests
that inﬁltrated monocytes/macrophages produce important
cytokines, growth factors, and matrix-remodeling proteases
(speciﬁcally metalloproteinases). Monocytes/macrophages
express markers typical of proinﬂammatory macrophages
(type M1) or remodeling macrophages (type M2) depending
on whether the implanted scaﬀolds are degradable or not
[13–16]. Additionally, recruited monocytes release vascular
endothelial growth factors and thus may be involved in
undesired neovascularization of CVTE implants [17].
Clearly, a better understanding of the underlying path-
ways appears crucial for controlling the fate of implants
and modulating inﬂammatory reactions in such a way as
to induce implant healing and remodeling as compared
to ﬁbrosis and/or degeneration. One way of approaching,
this issue is developing imaging modalities and discovering
new biomarkers of inﬂammation which would help further
understanding of inﬂammatory diseases and discerning
events related to inﬂammation in CVTE implants [18].
Examples include the detection of vascular cell adhesion
molecules, markers for proteases, integrin labeling and
uptake of oxidized low-density lipoprotein in atherosclerotic
lesions [19–22]. Circulating C-reactive protein has become
particularly favored as an inﬂammatory marker due to its
long half-life and chemical stability [23–25] in addition to its
ability to predict cardiovascular events [26] and evaluate the
eﬀectiveness of clinical anti-inﬂammatory treatment options
[7, 27].
3. Scaffolds for Cardiovascular
TissueEngineering
Tissue engineering (TE), aided by emerging stem cell
technology, holds immense potential for the treatment of
cardiovascular (CV) diseases, as progress has been made
in engineering the various components of the CV system,
including blood vessels, heart valves, and cardiac muscle
[28–31] .T h eg o a lo fC V T Ei st oc r e a t eo rr e g e n e r a t ea
functional structure populated with cells capable of contin-
uously remodeling the extracellular matrix (ECM). Optimal
replacements for failed CV components would be biocom-
patible tissues that have the potential to rapidly restore
the lost function and slowly regenerate by remodeling.
This is a bioengineer’s dream come true and increasingly
more reports show that we are slowly getting closer to
viable solutions. The speciﬁc concepts of TE include the
creation of a suitably shaped scaﬀold, repopulation with the
appropriate cells (endothelium, smooth muscle cells, ﬁbro-
blasts), ensuring that cells are placed in their appropriate
tissue “niche” (e.g., lumen, media, adventitia), promotion of
neovascularization (where needed), and dynamic mechan-
ical conditioning [32] to slowly adapt cells to loads and
prepare constructs for implantation. Scaﬀolds for CVTE
must be noncytotoxic, biocompatible, biodegradable with
safe by-products, and highly porous yet mechanically stable
for the appropriate functions [33]. Bioscaﬀolds derived from
xenogeneic ECM as well as synthetic polymers have been
used in numerous TE applications. ECM is the natural
scaﬀold for tissue and organ morphogenesis, maintenance,
and reconstruction following injury, and is associated with
constructive tissue remodeling. The 3D organization of its
components and the complexity of the composition clearly
distinguish the ECM from synthetic scaﬀolds [34]. The
processing of ECM biomaterials for medical use involves
decellularization of mammalian tissues in order to remove
all epitopes associated with cells, especially the terminal
galactose alpha 1,3 galactose (alpha-Gal) [35], expressed on
the cell surface of all mammals except those of humans andInternational Journal of Inﬂammation 3
old world primates [36]. It is known from earlier studies
that pure collagen scaﬀolds degrade slowly and do not calcify
in subdermal implantation models [37–39]. Aldehyde cross-
linked ECM calciﬁes after implantation [40], thus, limit-
ing the use of glutaraldehyde-treated valve bioprostheses.
Notably, increasing the extent of matrix cross-linking by
adding amine bridges [41] signiﬁcantly reduced calciﬁcation
when tested in a variety of animal models [42–45].
At early stages, scaﬀolds are inﬁltrated by macrophages
which degrade ECM slowly by means of secreted matrix
metalloproteinases (MMPs); at later stages scaﬀolds are
inﬁltratedbyﬁbroblastswhichinitiaterepairandremodeling
processes. Although degrading collagen scaﬀolds do not
accumulate calcium deposits in vivo, degrading elastin
scaﬀolds have a natural tendency to calcify unless stabi-
lized [46]. While the mechanisms of this process are still
under investigation, it is evident that matrix cytokines
(“matrikines”)suchaselastinpeptidescaninduceosteogenic
responses in smooth muscle cells and ﬁbroblasts and thus
mediate calciﬁcation [47]. Thus it is apparent that there is
a dire need for a method to stabilize elastin. Polyphenols
such as tannic acid and its more stable core compound,
pentagalloyl glucose (PGG) was shown to bind tightly to
elastin and in doing so stabilizes elastin ﬁbers suﬃciently
to reduce degeneration and calciﬁcation in animal models
of aneurysms and in bioprosthetic heart valves [48–51]. In
r e c e n ty e a r sw eh a v ee x t e n d e dt h eu s eo fP G Gt oE C M
scaﬀold stabilization for tissue engineering heart valves [37],
and vascular grafts [38]. Notably, when tested in vivo, PGG-
stabilized acellular porcine pericardium and carotid arteries
degraded at a slower rate than unstabilized scaﬀolds, did
not calcify and underwent remodeling, suggesting that PGG
could serve as an ideal stabilization agent for biological
scaﬀolds [37, 38].
4.Challenges inCardiovascular
TissueEngineering
Eﬀective clinical application of the TE scenario described
aboveraisesaseriesofchallengeslinkedto(1)thepreexisting
pathology, (2) the surgical procedure, and (3) the nature of
the implant.
Little is known about the eﬀect of the pathological status
of a tissue, organ, or patient on the fate of CVTE devices
and constructs. However it is reasonable to believe that the
preexistingpathologyorexistingriskfactorswouldinﬂuence
long-term outcomes of device implantation. For example,
implantation of a vascular graft in an atherosclerosis-prone
patient results in decreased patency [52].
T h es u r g i c a lp r o c e d u r em a ya l s oa ﬀect host reactivity.
In the ﬁrst several weeks, surgery-related tissue trauma
(much unrelated to the implant itself) induces an expected
inﬂammatory response coupled to a wound healing reaction.
The response follows the known pathways of inﬂammation
followed by repair and healing. This portion of the implant-
host interaction time line is necessary to heal the excised
tissues and establish a “working interface” between the
implant and host. Since the extent of the host response
depends on the degree of surgical injury, more and more
CVTE approaches envision devices that could be delivered
and implanted using less traumatic, minimally invasive
(percutaneous,laparoscopic,endovascular)approaches[53].
The nature of the implant could evidently have a
great impact on its clinical outcome. Ideally, the CVTE
implant should not be immunogenic, nor should it induce
thromboembolic complications, or excessive and prolonged
inﬂammation. Unfortunately, few biomaterials exist which
can be considered completely inert. For example, ePTFE and
Dacron vascular grafts function well in large diameter graft
applications without endothelial cell coverage but when used
in peripheral applications, one half of them occlude within
the ﬁrst ﬁve years of implantation [54].
A viable endothelium can drastically alter the outcomes
of synthetic prostheses; this was demonstrated by in vitro
endothelialization of ePTFE grafts, procedure pioneered by
Prof. Peter Zilla in South Africa more than 20 years ago
[55]. In this process, the patients’ own endothelial cells
were harvested and grown on synthetic ePTFE grafts prior
to implantation. This resulted in an improvement in graft
patencytovaluessimilar tothose obtainable withautologous
vessels [56].
Thus, to meet these challenges, novel CVTE approaches
should take into account preexisting pathology by “per-
sonalizing” implants to each patient. This includes use of
autologous cells and speciﬁc implants developed for speciﬁc
disease states. We also need to develop implants that attempt
to reduce surgical trauma to a minimum and prepare
noninﬂammatory materials which are protected by a healthy
endotheliallayer.Thefollowingsectionsprovidemoredetails
on inﬂammation and other challenges associated with use of
TE heart valves, vascular grafts and myocardium.
5. Heart ValveTissueEngineering
The hallmarks of valve pathology are ﬁbrosis in rheumatic
heart disease and calciﬁcation in aortic stenosis [11]. Post-
inﬂammatory scarring is one of the most cited mecha-
nisms of valvular pathology; this denotes correlations with
inﬂammation, but very little is known about the speciﬁc
mechanisms involved in the onset and progression of
heart valve pathology [6]. Jian et al. showed that as a
response to injury, calciﬁc degeneration in human valves is
characterized by localized endothelial damage, macrophage
inﬁltration, MMP secretion and activation, interstitial cell
transformation into an osteogenic phenotype, apoptosis
and calciﬁcation of devitalized cells and some processes
possibly mediated by TGF-beta1 [47, 57]. Information
obtained from human patient samples are just a snapshot
in time and in most circumstances reﬂect the end stages of
valvular disease. Currently, there is no eﬀective medication
available to limit, progression of heart valve diseases, and the
most common treatment is their surgical replacement with
mechanical devices or valves made from biological tissues.
It is estimated at present that 275,000 valve replacements
are performed annually worldwide using mechanical valves
andtissuevalves.However,themostphysiologicalprostheses4 International Journal of Inﬂammation
are the pulmonary autograft valves (transposition of the
livingpatient’sownpulmonaryvalveintotheaorticposition)
and the allograft valves (sterilized, cryopreserved human
cadaveric valves). Allografts exhibit excellent durability after
implantation but are not readily available and represent only
a small percentage of total valve replacements.
The main issue that emerged during clinical investiga-
tions of replacement heart valves was their limited durability
which limits their use in young patients. Reoperation
following valve replacement surgery, for the purpose of
retrieving and replacing the defective device, is a relatively
common event and occurs within 10–15 years after initial
valve surgery [58]. Newer tissue valve models claim better
performances [59], but this remains to be determined.
Histological, ultra structural, and biochemical aspects of
degenerated explanted tissue valves are similar to those of
native human-diseased heart valves. The major processes
that contribute to this “new pathology” of replacement
heart valves are tissue calciﬁcation and mechanical damage.
Calciﬁcation may occur independent of mechanical damage
[60] but may also be accompanied by tissue abrasion,
tearing and perforations. There is a startling paucity of basic
knowledge on calciﬁcation mechanisms, as well as action of
treatments that presumably mitigate calciﬁcation [40].
The goal of heart valve tissue engineering (HVTE) is to
reestablish proper valve functions while allowing for slow
r e g e n e r a t i o no fan e wv a l v et i s s u e .T h e s et w op r o c e s s e sh a v e
to occur simultaneously without inﬂuencing each other or
promotingthrombosis,coagulationorinﬂammation.Imme-
diately upon implantation, the device needs to function
properly, to withstand the harsh biomechanical regime of
the aortic valve environment and induce left ventricular
remodeling. While performing these functions, the device
is expected to be perfectly “tuned” so that endothelial and
interstitial cells slowly remodel the ECM without altering
mechanical properties in the process. This is a challenging
task, as the balance between MMPs and their inhibitors is
very delicate [58].
Strategies for HVTE fall into several categories [61]. A
ﬁrstapproachisimplantationofdecellularizedvalvematrices
and relying on host cells to repopulate and remodel the
scaﬀolds. This approach has been limited by the fact that
scaﬀoldsarenotporousenough,cellsdonotreadilyinﬁltrate
the scaﬀolds and human acellular valves are in short supply.
Porcine acellular valves have been implanted in recent years
in several clinics, but their use is currently limited due to
early failure of several valves in clinical studies [62]. Some
valves exhibited severe inﬂammation after only 2 days of
implantation, leading to structural failure at 7 days and
degeneration associated with severe foreign body reaction
dominated by early neutrophils and macrophage inﬁltration
and late lymphocyte reactions. These reactions were the
result of incomplete cell removal and other manufacturing
problems [62] .As e c o n da l t e r n a t i v ew o u l db et or e p o p u l a t e
decellularized valve matrices with appropriate cell types
in vitro before implantation. Recently we have shown
that in vitro endothelialization of acellular porcine aortic
valves is possible and that surface-seeded endothelial cells
withstood bioreactor testing in pulmonary conditions for
3 weeks showing excellent retention and viability [63]. A
third strategy involves assembly of synthetic biodegradable
matrices populated by cells and bioreactor conditioning to
express adequate properties before implantation [29, 64].
Whilethisapproachseemsappealing,thepolymericmatrices
lacksuﬃcientmechanicalstrength[65],developﬁbrosis[64]
and have not yet withstood the test of time under arterial
pressures.
5.1. Prognosis. Tissue engineering of heart valves is one
of the most daunting tasks in the ﬁeld of regenerative
medicine. Technologically, there are numerous hurdles to
overcome before implantable living heart valves become
a reality. Valvular scaﬀolds have to function immediately
after implantation, endure signiﬁcant mechanical stress, and
also maintain stable matrix homeostasis while undergoing
adaptation to altered hemodynamics and somatic growth.
The presence of living interstitial cells and a continuous
layer of endothelial cells covering the scaﬀolds would prove
highly beneﬁcial ensuring proper matrix homeostasis and
protection from inﬂammation. Further studies are needed to
make the dream of HVTE a reality.
6. Vascular TissueEngineering
Current treatmentoptions forvasculardiseases, regardlessof
locationinthevasculature,includeballoonangioplasty,stent
placement, graft bypass surgery, and use of pharmacological
agents [66–70]. The total need for vascular grafts has been
estimated to be more than 1.4 million in the USA alone
[71]. These can be divided into three categories, in order of
decreasing diameter. The large and medium caliber synthetic
grafts are used in the thoracic and abdominal cavities with
good long-term outcomes. Almost 1,200,000 small-caliber
grafts (<6mm) are used every year for vascular access, to
relieve lower limb ischemia and for coronary bypass surgery.
Autologous veins or arteries are the “gold standard” for
replacement of small caliber arteries, but in 30–40% of
patients these are not available due to prior harvesting or
preexisting conditions. In these latter cases synthetic grafts
are used, but they provide poor outcomes, as 50% of these
will occlude within 5 years [72], potentially leading to
amputation.
Tissue engineering vascular grafts (TEVGs) entails the
growingoflivingvessels,byusingcellsandscaﬀolds,aloneor
in combinations. The functional requirements must include
the following: nonthrombogenicity, adequate burst pressure
and compliance, appropriate remodeling responses, and
vasoactivity. Equally important is the propensity to elicit
inﬂammation and to resist proinﬂammatory milieus when
implanted in compromised patients. Traditionally, TEVGs
have been constructed from both biological and synthetic
scaﬀolds [73] with or without repopulation with autologous
cells [72]. For these purposes, mesenchymal stem cells
derived from a patient are puriﬁed, expanded, and exposed
tospeciﬁcbiologicalcuestoincitediﬀerentiationintodesired
cell types, and the TEVGs are then seeded with cells [74, 75].
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to increasing loads and increase overall performance [76].
Excellent results have been reported in animal testing and
also limited number of clinical trials [77]; however, the long-
term eﬃcacy of these grafts is still uncertain. Attaining a
properbalancebetweenscaﬀolddegradationandremodeling
is still under investigation. Rapid degradation is clearly
detrimental and could have dramatic consequences. Slow
degradation of scaﬀolds is a prerequisite for successful
TEVGs; however, scaﬀold degradation products (collagen,
elastin, ﬁbronectin and laminin peptides) in synergism with
TGF-beta and other cytokines may induce the diﬀerentiation
of smooth muscle cells and ﬁbroblasts into osteoblast-like
cells and myoﬁbroblasts, respectively [47, 78–80].
6.1. Existing Inﬂammation: The Bane of Tissue-Engineered
Vascular Grafts. One of the most complicated aspects of
designing a replacement for diseased tissue is incorporating
measures which prevent the device from succumbing to the
same fate as the diseased tissue it is replacing. The clinical
experience with the transplantation of vascularized organs
has uncovered several aspects useful for TEVGs. In heart
transplants, it has been reported that as the duration of time
after-implant increases, patient mortality also increases [81].
Theculpritforthisproblemhasbeendenotedasgraftarterial
disease(GAD)[82],characterizedbyintimalhyperplasia,the
denudation of the medial layers, ﬁbrosis of adventitial layers,
and vasoconstriction [83]. GAD diﬀers from atherosclerosis
by not being related to fatty streak deposition and by
developing circumferentially and not focally [84]. Shimizu
and Mitchell [82] also reported that symptoms of ischemia
are often masked in transplanted tissues due to the lack of
innervation, only furthering the convolution of the disease.
Therefore, even following successful organ transplantation
and the necessary immunosuppression medication that
ensues, GAD can arise and threaten the health of both
the transplanted organ and the patient. Placing TEVGs
into a compromised site would likely decrease the life of
the vascular construct, especially due to the expression of
chemokines that recruit inﬂammatory cells which are key
to allograft rejection [85, 86]. GAD has been reported
to incite host ingrowth of endothelial cells and intimal
smooth muscle-like cells, which are reported to be diﬀerent
from medial-smooth muscle cells [87], into the allograft
vasculature [88–90]. On the upside, such cellular ingrowth
properties could potentially be harnessed to further TE
strategies for vascular constructs.
Atherosclerosis has similarities to GAD but ultimately
diﬀers in the involvement of lipoproteins and foam cells
entrapped within the intima, which form the character-
istic localized fatty streaks [23]. After several decades of
research, we now know that atherosclerosis is a conse-
quence of chronic inﬂammation [91] with elements of
immune system activation [92]. The main questions that
bioengineers have to address now are how to develop a
TEVG that would be protected from atherosclerosis after
implantation in an atherosclerotic prone patient? Will
an endothelium that is healthy at implantation become
dysfunctional under systemic insults, and, therefore, not
be capable of preventing local inﬂammatory signals? Is
control of systemic inﬂammation in fact the critical step
to success? Regardless of the mechanisms perpetuating
disease progression, studies into pathogenesis of atheroscle-
rosis and other inﬂammatory diseases point to the activa-
tion of endothelial cells as the critical starting point for
the disease [23, 93]. Thus, knowledge of mechanisms of
endothelium activation and its role in promoting inﬂam-
mation would need to be incorporated into future TEVGs
[23].
6.2. Prognosis. The ﬁeld of vascular tissue engineering
necessitates advances in cell seeding, cell ingrowth, elastin
biosynthesis, and nutrient perfusion before any large clinical
breakthroughsaretobeexpected.Scaﬀoldsneedtobealtered
so that they are less inﬂammatory and also that they resist
and perform well in proinﬂammatory environments. For
these objectives, testing TEVGs in healthy and pathological
animal models would be useful. The ability of vascular grafts
to fully remodel into de novo formed arteries still needs to be
evaluated extensively.
7.MyocardialTissueEngineering
Aside from replacements for ailing valves and devices used
to occlude septal defects, applications for tissue engineering
which deal solely with the myocardium are very limited.
A major area of interest, however, is the restoration of
cardiac muscle functionality in patients who have suﬀered
an acute myocardial infarction (AMI) and are at risk for
developing congestive heart failure (CHF) [94–97]. The
acute inﬂammatory response which occurs subsequently
to the death of ischemic cells is culpable for scar tissue
development, which, in turn, is responsible for global
remodelingoftheheartand,ultimately,developmentofCHF
[24, 94, 96]. This scenario is diﬀerent from inﬂammation
in heart valves or blood vessels because the post-AMI
inﬂammatory response is a consequence of or response to,
ischemia. Injury leads to the activation of inﬂammation,
ECM degradation and MMPs and TGF secretion which
in turn activate cardiac ﬁbroblasts to initiate ﬁbrosis [98–
100]. Clearly, vascular endothelium is the main barrier that
controls tissue reactivity to cytokines and determines the
outcome of tissue inﬂammation [101]. Tissue engineering
approaches to the regeneration of the myocardium following
AMIstrivetoattenuatethegeometricalalterations(dilatedor
ischemic cardiomyopathy) which take place in the ventricles,
concurrently slowing or halting progression towards CHF
[95, 102].
The remainder of this section will discuss only eﬀorts
to regenerate the myocardium which involve the use of
engineered heart tissue (EHT) [103] constructs, deﬁned
as consisting of a scaﬀold composed of synthetic material,
natural material, or any combination thereof and at least one
type of cell attached to the scaﬀold. Ideally, the EHT should
be prevascularized, posses similar mechanical properties
to ventricular myocardium, be contractile and integrate
well within existing tissues. More importantly it should be6 International Journal of Inﬂammation
noninﬂammatory and also resist the proinﬂammatory envi-
ronment surrounding the infarcted area. We will speciﬁcally
address several points which are relevant to the feasibility
of using EHT to treat ischemic cardiomyopathy, including
the interaction of EHT with existing scar tissue, the host
response to the construct and the challenges of implanting
EHT in patients with poor cardiovascular health or other
preexisting conditions.
7.1. Complications from Existing Scar Tissue. The inﬂamma-
tory response following AMI occurs rapidly. It is estimated
that necrosis of cardiomyocytes begins 20–30 minutes after
the initial blockage of the coronary vasculature [104]. The
current gold standard in clinical care after-AMI is percutane-
ous coronary intervention (PCI), a transcatheter procedure
wherein a balloon is used to dilate the vessel lumen imme-
diately adjacent to the site of thrombotic occlusion, thus
restoring ﬂow to the downstream tissues [105]. Currently,
chest pain centers and cardiac care units have set a bench-
mark “door-to-balloon” time of 90 minutes in order to limit
the extent of damage produced by AMI [106, 107]. While
minimizing door-to-balloon time is critical, it is diﬃcult
to imagine achieving the reperfusion of the ischemic tissue
before cardiomyocyte necrosis sets in.
When necrosis occurs, so will inﬂammation. And with a
lack of intrinsic regenerative capability in the myocardium,
the necrotic core will be completely remodeled into ﬁbrous
tissue in 2–6 weeks after-AMI [97, 108, 109]. The implica-
tions of this abnormal remodeling are twofold: (a) tissue-
engineering strategies currently hold the most promise for
regeneration of the myocardium because they introduce
new, viable cells into an environment that is not conducive
to regeneration on its own [94]; (b) tissue engineered
constructs will have to be placed over or adjacent to
scar tissue unless the construct is implanted immediately
following AMI (before scar tissue can be formed) or the
scar tissue is surgically resected prior to the implantation
of the construct [102]. In order to implant a construct
immediately after AMI, it would need to be ready before
the event, in an “oﬀ the shelf” fashion. This possibility is
precluded by complications that arise due to autologous cell
sourcing and the need for in vitro cell proliferation, seeding,
and preconditioning in a bioreactor. Such a process could
take several weeks, if not months, to complete and could not
beneﬁtthepatientimmediatelyunlesstheAMIwaspredicted
[95, 102, 108].
W hetherornotgraftingEHT[103]directlytotheﬁbrotic
scar inhibits proper adherence, and the perfusion of the
graft with the host tissue through an inﬂammatory response
is unclear. A number of studies have reported positive
outcomes when implanting EHT on top of infarct scars
created in animal models [110–112]. When EHT constructs
are not placed directly on the epicardium over the scar,
but rather at the endocardial surface (by means of a Dor
procedure) [113] or in a depression made by the resection
of the scar tissue, solid engraftment has been repeatedly
achieved [114–116]. These opposing implantation methods
will need to be compared for eﬃcacy by performing both
with a single type of EHT, then perhaps the diﬀerence, if one
exists, can be elucidated.
Equally conﬂicting results were reported by two groups
who implanted “prevascularized” EHT in a nude rat model
(without infarct). One group reported that their construct
integrated well, forming microvasculature which perfused
with the host’s and resembled viable myocardium [117],
while another group observed ﬁbrotic encapsulation of their
EHT graft. Ironically, the latter occurred in rats which were
on an immunosuppression regimen [97]. What is clear,
however, is that cell-free constructs composed of synthetic
material can be at risk for poor performance when im-
planted in or adjacent to the myocardium, possibly due to
inﬂammation. Stuckey et al. reported that patches of tita-
nium oxide-reinforced poly(ethylene terephthalate)/dimer
fatty acid implanted onto infarcted rat hearts produced
extensive necrosis in the adjacent healthy host tissue, most
likely due to micromotions between the graft and host
caused by compliance mismatch [94]. Similarly, another
group reported extensive foreign body response, thrombus
formation, necrosis, and calciﬁcation associated with an
ePTFE graft that was implanted on the endocardial surface
of the infarcted heart in a pig model [115]. It is evident that
control of inﬂammation in EHT is of essence for the success
ofimplantedscaﬀoldsandthatthismightbeenhancedbythe
preexisting “inﬂamed” status of the ischemic myocardium.
7.2. Characterizing the Host Response. Positive outcomes in
designing EHT are measured by criteria such as the attenu-
ation of ventricular wall remodeling or dilation, perfusion
of the graft by the host vasculature, electrical coupling
of the cardiomyocytes in the graft with those of the host
(via the formation of connexins or gap junctions), and the
avoidance of inﬂammation, encapsulation, or calciﬁcation
[95,102,108].Tissueengineeringforthisspeciﬁcapplication
is still in its early stages. Most implantation studies have not
been run for longer than 3 months and have focused on
establishing proof of principle rather than studying the long-
term performance of EHT constructs [110–112, 114–116].
Assuch,thereisverylittledataavailableinregardstochronic
inﬂammatory responses or calciﬁcation with which to make
a prognosis for the long term viability of these constructs.
The ﬁrst ever clinical trial (MAGNUM-trial) involving
an EHT construct was begun in 2003 and used autologous
bone marrow cells (BMC) seeded onto a 3D collagen type
Is c a ﬀold [118]. The construct was implanted over the
epicardial surface of the postinfarct scar in a group of
10 patients while they were undergoing coronary artery
bypass grafting surgery. Followup at 10 months indicated
prevention of cardiac remodeling and thickening of the scar
(viacellingrowth)withfunctional,healthytissue.Thesewere
assessedusingechocardiographyandsingle-photonemission
computed tomography [119]. There were no indications of
immune or inﬂammatory reactions, no arrhythmias, and the
EHT appeared to integrate well with the host tissue. It is
important to note that this particular EHT construct was not
intended to be functional, meaning it was neither contractileInternational Journal of Inﬂammation 7
nor vascularized [102]. Its mechanism of action was one of
providing “passive” support, and the collagen matrix most
likely acting as a stable microenvironment from which the
BMC could secrete paracrine signals to the healthy cells in
the peri-infarct tissue. A construct of this type, implanted
in this fashion, would not be at risk for developing either
GAD or atherosclerosis, because the cells were autologous
andtheneovasculatureformedwithinitwouldnotconsistof
vesselslargeenoughtobeaﬄictedwithsuchconditions[120,
121]. Calciﬁcation, however, might develop in this construct
because type I collagen is known to predispose to forming
nucleation sites for calcium deposits [122]. Furthermore,
the mechanical stresses and deformations imposed on the
construct via the continuous, repetitive contraction of the
heart might accelerate mineralization [122]. It is noted that
the authors of the MAGNUM trial make no mention of
calciﬁcation being observed in the followup, especially since
echocardiography can be used to image calcium [123]. In
the case of the MAGNUM trial, it is probable that more
time must elapse before evidence of the activity of the
typical culprits in the failure of tissue-engineered constructs
emerges.
7.3.EngineeredHeartTissueintheCompromisedPatient. The
vast majority of patients who could beneﬁt from a clinically
feasible and cost-eﬀective EHT have some form of cardiovas-
culardisease[95].WhendevelopingEHT,researchersshould
rid themselves of the illusion that potential candidates for
their therapy will be a tabula rasa of health. Rather, they
should prepare EHT constructs to withstand a hostile, dis-
eased environment. In the MAGNUM trial discussed earlier,
for example, 11 of the 20 participants were hypertensive,
13 were hypercholesterolemic, 7 were diabetic, and 10 were
smokers [118].
In terms of inﬂammatory processes, a few of the most
threatening conditions to the long-term viability of EHT are
atherosclerosis, GAD, and arteriolosclerosis. Atherosclerosis
is the most well known of these diseases, as it is implicated
in having a causal role in both CHD and peripheral artery
disease. Characteristic atheromatous plaques or lesions also
indicate the possibility of tissue calciﬁcation [120, 124,
125]. GAD has been observed to occur predominantly
in implanted allografts, which contain immunogenic cell
constituents [121]. EHT constructs, however, should ideally
consist of nonimmunogenic ECM proteins seeded with
autologous cells, rendering them free from concerns about
GAD or transplant vasculopathy [121]. Finally, arterioloscle-
rosis, or the thickening of the intimal layer in arterioles due
to hyperplasia or hyaline matrix deposition, could occur in
EHT[120].EHTgraftsimplanted inhypertensiveordiabetic
patients would be at an increased risk of contracting arteri-
olosclerosis because these risk factors are closely interrelated
[120]. Both atherosclerosis and arteriolosclerosis could have
amajorimpactupontheviabilityofEHTconstructs,because
such constructs will most likely contain a preformed or
preserved vascular network that will stenose or occlude if
these diseases are present, leading to ischemia and necrosis
of the cells in the construct.
7.4. Prognosis. It is diﬃcult to make conjectures about the
ultimate success or failure of EHT constructs. Given the
requirements placed upon them and the mechanisms or
processes that might be at work in vivo, producing an
EHT construct that remains viable for some time will be
a challenging task. In the future, more clinical trials of
EHT constructs need to be conducted so that a larger
data set can be formed and the eﬃcacy of their outcomes
assessed. The pathways which mediate the inﬂammatory
processesofatherosclerosisandarteriolosclerosis,theﬁbrous
remodeling process, and the unfriendly microenvironment
of patients with these conditions need to be elucidated so
that drug discovery eﬀorts can generate new prophylactic
drugs. While such drugs could reduce the patient population
in need of EHT treatments, the current demand is so
great that the need for them would still be obviated
[95]. Until such drugs are available, however, EHT needs
to be developed so as to withstand the hostile environs
in patients compromised by diseases. Short of this, the
best case scenario is that patients receiving EHT grafts
will cease or seek treatment for risky behaviors such as
smoking, hypertension, hypercholesterolemia, or diabetes
and initiate beneﬁcial behaviors like engaging in physical
activity or adjusting dietary intake and nutrition. Sadly,
inﬂammatory processes are self perpetuating in patients
aﬄicted with cardiovascular disease. The progression to
CHF can begin with one chronic inﬂammatory condi-
tion which begets another acute inﬂammatory response,
constituting a chain of causality. If researchers working
to develop EHT can overcome the inherent challenges
associated with it, they can alleviate the devastation CVD
causes so many patients and their families throughout the
world.
8. FinalRemarks
CVTE holds great potential to solve some of the biggest
current health issues. The prospects of using scaﬀolds, cells,
and chemical or mechanical stimuli to create functional
tissues such as valves, arteries and myocardium are hugely
exciting as we attain “magical powers” previously unimag-
inable. After an initial period of hype and hope, we are
now closer to clinical application of CVTE; however, we
need to increase our control over inﬂammation and its
clinical consequences. One approach could involve making
scaﬀolds from carefully screened, intact molecules (synthetic
of biologic), and repopulating the scaﬀolds with interstitial
cells and endothelial cells in vitro. This should be followed by
conditioning the constructs in bioreactors until cells “gain
control” over the remodeling process and the constructs
show clear signs of regeneration. Only then would tissue
engineering products be ready for implantation in the
targeted dynamic cardiovascular sites. While we continue
to trek towards the unknown at warp speed, we need to
focus more on the endothelium, the “ﬁnal frontier”. This
will eventually determine whether novel CVTE devices will
successfully help thousands of patients in need of tissue
regeneration and repair.8 International Journal of Inﬂammation
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